Immunicum develops immunotherapies for therapeutic treatment of cancer. The company's patented platform technology is sprung from years of research within the field of transplantation immunology.

The unique vaccine concepts are based on using allogeneic dendritic cells as adjuvants and can either be combined with allogeneic tumor antigens or use the patients' own tumors as autologous antigen source. The adjuvants are expected to ensure an optimal activation of the immune system against any type of cancer. The vaccines allow for cost effective large scale production, effective storage and transportation, and easy administration to patients in public and private health care centers.